Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Sexually Transmitted Infections|February 9, 2026
Cross-sectional evaluation of a lateral flow assay for point-of-care detection of Neisseria gonorrhoeae in asymptomatic individuals at primary healthcare facilities in South AfricaRemco P H Peters, Jeffrey D Klausner, Laura T Mazzola, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 TrialSarah Baker, Will Jiang, Benjamin Mou, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2025
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 TrialSarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, et al.
BMC Cancer|October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5Robert Olson, Mitchell Liu, Alanah Bergman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 29, 2021
Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's diseaseHuntington Potter, Jonathan H Woodcock, Timothy D Boyd, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2025
Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapyJonas Willmann, Sarah Baker, Hanbo Chen, et al.
BMC Cancer|May 7, 2020
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trialRobert Olson, Lindsay Mathews, Mitchell Liu, et al.
JAMA Oncology|September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical TrialRobert Olson, Will Jiang, Mitchell Liu, et al.
International Journal of Radiation Oncology, Biology, Physics|April 11, 2025
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 TrialAiden Kooyman, Jee Suk Chang, Mitchell Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trialReno Eufemon Cereno, Benjamin Mou, Sarah Baker, et al.
Pageof 14